Swedbank AB increased its position in Savara Inc. (NASDAQ:SVRA – Free Report) by 54.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 850,000 shares of the company’s stock after buying an additional 300,000 shares during the quarter. Swedbank AB’s holdings in Savara were worth $5,126,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Prudential Financial Inc. bought a new position in shares of Savara in the 2nd quarter worth $30,000. BNP Paribas Financial Markets lifted its holdings in shares of Savara by 52.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after purchasing an additional 4,626 shares in the last quarter. Brevan Howard Capital Management LP bought a new position in shares of Savara in the 2nd quarter worth $33,000. Russell Investments Group Ltd. lifted its holdings in shares of Savara by 930.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after purchasing an additional 9,463 shares in the last quarter. Finally, CIBC Bancorp USA Inc. bought a new position in shares of Savara in the 3rd quarter worth $44,000. 87.93% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
SVRA has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating on shares of Savara in a report on Monday, March 16th. William Blair set a $10.00 price objective on Savara in a research note on Monday, March 16th. Oppenheimer began coverage on Savara in a research note on Friday, April 24th. They set an “outperform” rating and a $11.00 price objective on the stock. Wall Street Zen cut Savara from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.13.
Savara Price Performance
Shares of NASDAQ:SVRA opened at $5.14 on Wednesday. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. The stock’s fifty day simple moving average is $5.29 and its two-hundred day simple moving average is $5.53. Savara Inc. has a 1-year low of $1.89 and a 1-year high of $7.01. The stock has a market cap of $1.05 billion, a PE ratio of -9.18 and a beta of 0.28.
Savara (NASDAQ:SVRA – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). As a group, analysts forecast that Savara Inc. will post -0.58 EPS for the current fiscal year.
About Savara
Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.
The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.
Recommended Stories
- Five stocks we like better than Savara
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc. (NASDAQ:SVRA – Free Report).
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.
